BioGeneration Ventures is investing in the next generation of Life Sciences companies in the Netherlands.
Business Model:
Revenue: $3.8M
Employees: 11-50
Address: Gooimeer 2-35
City: Naarden
State: drente
Zip: 1411 DC
Country: NL
BioGeneration Ventures is investing in the next generation of Life Sciences companies in the Netherlands. BioGeneration Ventures invests in Dutch start-up and early stage life sciences companies. The BioGeneration Ventures team is specialized in the evaluation and management of early stage companies. Their involvement goes beyond the financial investment. They work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of their portfolio company&s;s technologies. BioGeneration Ventures began operating in 2006 and the fund is backed by the Netherlands Genomics Initiative (NGI) and the Netherlands Organisation for Scientific Research (NWO) in combination with the holding company of Leiden University and ABN-AMRO Capital as lead private investors.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2017 | Cristal Therapeutics | Venture Round | 0 |
4/2014 | Mucosis | Venture Round | 0 |
9/2007 | Mucosis | Series A | 0 |
1/2016 | Mucosis | Venture Round | 6.2M |
11/2022 | FundaMental Pharma | Seed Round | 10.4M |
1/2007 | Noviogendix Holding | Venture Round | - |
2/2013 | Dezima Pharma | Venture Round | 18.6M |
5/2023 | VarmX | Series B | 0 |
11/2021 | Dunad Therapeutics | Series A | 0 |
1/2020 | Dualyx | Venture Round | - |
1/2019 | New Amsterdam Pharma | Venture Round | - |
12/2014 | Cristal Therapeutics | Venture Round | 7.5M |
8/2017 | Mellon Medical | Series B | 7.1M |
1/2022 | River BioMedics | Seed Round | 0 |
11/2022 | CatalYm | Series C | 0 |
11/2020 | Catalym | Series B | 59.3M |
2/2020 | Azafaros | Series A | 27.5M |
1/2020 | NorthSea Therapeutics | Series B | 40M |
6/2017 | VarmX | Seed Round | 1.1M |
5/2019 | Confo Therapeutics | Series A | 33.6M |
5/2023 | Dualyx | Series A | 0 |
7/2020 | VarmX | Series B | 36.3M |
12/2021 | NorthSea Therapeutics | Series C | 0 |
1/2013 | SurgVision | Venture Round | - |
12/2017 | NorthSea Therapeutics | Series A | 29.4M |
7/2018 | VarmX | Series A | 8.7M |
1/2008 | Progentix Orthobiology | Venture Round | - |
3/2018 | Escalier Biosciences | Series B | 19M |
12/2009 | Medisse | Venture Round | - |
6/2017 | Scenic Biotech | Series A | 7.3M |
2/2014 | Synaffix BV | Series A | - |
2/2022 | Complement Therapeutics | Seed Round | 5.7M |
1/2020 | Tiga TX | Venture Round | - |
7/2018 | Azafaros | Seed Round | - |
7/2020 | Citryll | Series B | 0 |
1/2018 | Mironid | Venture Round | - |
3/2009 | FlexGen | Private Equity Round | - |
1/2021 | Complement Therapeutics | Seed Round | - |
3/2022 | Scenic Biotech | Series A | 0 |
4/2023 | Complement Therapeutics | Series A | 0 |
1/2019 | Genase Therapeutics | Venture Round | - |
9/2022 | Phosphoenix | Pre Seed Round | - |
3/2013 | AcertaPharma | Series A | 60M |
9/2009 | arGEN-X | Series A | 13.6M |
1/2014 | Staten Biotechnology | Venture Round | - |
2/2010 | arGEN-X | Series A | 4.5M |
1/2020 | Fibrocor Therapeutics | Venture Round | - |
11/2012 | Lanthio Pharma | Series A | 6.2M |
3/2022 | Scenic Biotech | Series A | 0 |
2/2022 | Complement Therapeutics | Seed Round | 0 |
1/2022 | River BioMedics | Seed Round | 0 |
12/2021 | NorthSea Therapeutics | Series C | 0 |
11/2021 | Dunad Therapeutics | Series A | 0 |
1/2021 | Complement Therapeutics | Seed Round | - |
11/2020 | Catalym | Series B | 0 |
7/2020 | VarmX | Series B | 0 |
7/2020 | Citryll | Series B | 0 |
2/2020 | Azafaros | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|